Consejo Nacional de Salud

148 Campbell T, Shulman N, Johnson S, Zolopa
A, Young R, Bushman L, Fletcher C, Lanier
R, Merigan T, Kuritzkes D. Antiviral Activity
of Lamivudine in Salvage Therapy for
Multidrug-Resistant HIV-1 Infection. Clinical
Infectious Diseases 2005; 41:236–42
http://www.journals.uchicago.edu/doi/
full/10.1086/430709 [Consulta: 6 de
Noviembre del 2008]
149 Cozzi-Lepri A, De Luca A, Phillips A, Bongiovann
Mi, Di Giambenedetto S, Mena M,
Moioli MC, Arlotti M, Sighinolfi L, Narciso P,
Lichtner M, Cauda R, d’Arminio Monforte
A, A Comparison between Abacavir and
Efavirenz as the Third Drug Used in Combination
with a Background Therapy Regimen
of 2 Nucleoside Reverse-Transcriptase Inhibitors
in Patients with Initially Suppressed
Viral Loads. The Journal of Infectious Diseases
2006; 194:20–8
http://www.journals.uchicago.edu/doi/
pdf/10.1086/504265 [consulta: 15 de
Noviembre 2008].
150 Ibíd., 144
GRUPO J | Antiinfecciosos para uso sistémico
327
J